
## Complex Case Reviews with BioMatrix<sup>TM</sup> Family of Stents

#### David Martí Sánchez Associate Professor of Cardiology Madrid, Spain


#### **The Dream of Any Interventionalist**



# **BioMatrix**<sup>TM</sup>

Family


#### **BioMatrix<sup>™</sup> Family of Stents**
















#### **BioMatrix<sup>™</sup> Family of Stents**

	BIOMATRIX NEOFLEX	BIOMATRIX ALPHA	BIOFREEDOM
Platform	Juno	Chroma	Juno
Stent material	Stainless steel	Cobalt-Chromium	Stainless steel
Strut thickness	120µm	84–88 µm	120µm
Polymer material	PLA		N/A
Polymer type	Abluminal Biodegradable Polymer		Polymer- and carrier-free
Antiproliferative drug release	Biolimus (A9) (15.6µg/mm2) Co-released with polylactic acid and completely desolves into CO2+H2O after a 6-9 months period.		Biolimus (A9) (15.6µg/mm2) 98% released after 28 days


#### **BioFreedom Stent**








### **Other Attractive Features**



Ng J, et al. Int J Cardiol. 2016:171

Ormiston J, et al. Circ Cardiovasc Interv 2014;62


#### **LEADERS All Corners, 5-Year Results**



Serruys et al., TCT 2012

#### Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk


Inclusion Criteria Applied (1.7 criteria / patient)



Urban P, et al. N Engl J Med. 2015:2038

#### **LEADERS FREE Trial**


#### Cardiac death, myocardial infarction, or ST




Urban P, et al. N Engl J Med. 2015:2038

# Polimer free

Open cell Long & Radial Strength




#### **Defining HBR Criteria**




P Urban et al. Circulation 2919: 240-261

# Impact of Anemia on the Risk of Bleeding in Older Adults Receiving PCI



Martí D, et al. Am J Cardiol. 2020 (in press)



#### **Case Presentation**

- 90 M
- Past MHx
  - T2DM
  - Mild cognitive impairment

- NSTEMI
- ECG: STD V4-V6
- HB 14.0, creat 0.78
- LVEF 54%
- Early invasive Rx (MOSCA FRAIL RCT)

#### **Diagnostic Angio**







#### **Technique**

- ✓ Ad hoc LCA PCI, 2nd procedure RCA PCI
- ✓ Femoral crossover (8F GC)
- ✓ Lesion preparation 2.5 & 3.0 NC balloons
- ✓ Stenting:
  - ✓ LM-LAD: 3.5/14 BIOFREEDOM
  - ✓ LM-LCX: 3.5/18 BIOFREEDOM
  - ✓ Mid LAD: 3.0/18 BIOFREEDOM
  - ✓ Distal LAD: 2.5/11 BIOFREEDOM
  - ✓ MO: 2.5/8 BIOFREEDOM

✓ LM postdilation: 3.5 mm NC secuential FKBI

#### **Final Result**





#### Thank you!